The neurobiological correlates of childhood adversity and implications for treatment

Acta Psychiatrica Scandinavica

Volumn 128, Issue 6, 2013, Pages 434-447

  Tyrka, A R ^a,b   Burgers, D E ^a   Philip, N S ^a,b   Price, L H ^a,b   Carpenter, L L ^a,b  

^a BUTLER HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Childhood abuse; Early life stress; Neurobiology; Treatment

Indexed keywords

ADRENALIN; ARGIPRESSIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CYCLOSERINE; FLUOXETINE; GLUCOCORTICOID RECEPTOR; MIFEPRISTONE; NEFAZODONE; NEUROTROPHIC FACTOR; NEUROTROPHIN; PLACEBO; PROPRANOLOL; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1B RECEPTOR ANTAGONIST;

ACUTE STRESS; ANXIETY DISORDER; APPETITE; ARTICLE; BEHAVIOR CHANGE; BORDERLINE STATE; CELL AGING; CHILDHOOD; CHILDHOOD DISEASE; CLINICAL DECISION MAKING; DEPRESSION; DEPRESSIVE PSYCHOSIS; DRUG EFFICACY; EARLY LIFE STRESS; ENVIRONMENTAL EXPOSURE; EPIGENETICS; EXERCISE; GENE EXPRESSION; GENERALIZED ANXIETY DISORDER; GENETIC VARIABILITY; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MAJOR DEPRESSION; MEDITATION; METABOLIC SYNDROME X; MONOAMINERGIC SYSTEM; MOOD DISORDER; NEGATIVE FEEDBACK; NEUROBIOLOGY; NEUROENDOCRINE DISEASE; NEUROIMAGING; NONHUMAN; PATHOGENESIS; POSTTRAUMATIC STRESS DISORDER; POVERTY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOTHERAPY; SHORT COURSE THERAPY; SUICIDE; TELOMERE SHORTENING; TREATMENT OUTCOME; WORKING MEMORY; YOGA;

CHILDHOOD ABUSE; EARLY-LIFE STRESS; NEUROBIOLOGY; TREATMENT;

ANIMALS; CHILD; CHILD ABUSE; HUMANS; LIFE CHANGE EVENTS; STRESS, PSYCHOLOGICAL;

EID: 84887401317     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12143     Document Type: Article

References (107)

1. Green JG, McLaughlin KA, Berglund PA et al. Childhood adversities and adult psychiatric disorders in the national comorbidity survey replication I: associations with first onset of DSM-IV disorders. Arch Gen Psychiatry 2010;67:113-123.
2. Dozier M, Albus K, Fisher PA, Sepulveda S. Interventions for foster parents: implications for developmental theory. Dev Psychopathol 2002;14:843-860.
3. Lupien SJ, McEwen BS, Gunnar MR, Heim C. Effects of stress throughout the lifespan on the brain, behaviour and cognition. Nat Rev Neurosci 2009;10:434-445.
4. McCrory E, De Brito SA, Viding E. Research review: the neurobiology and genetics of maltreatment and adversity. J Child Psychol Psychiatry 2010;51:1079-1095.
5. Kaffman A, Meaney MJ. Neurodevelopmental sequelae of postnatal maternal care in rodents: clinical and research implications of molecular insights. J Child Psychol Psychiatry 2007;48:224-244.
6. Sapolsky RM, Romero LM, Munck AU. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev 2000;21:55-89.
7. Dallman MF, La Fleur SE, Pecoraro NC, Gomez F, Houshyar H, Akana SF. Minireview: glucocorticoids-food intake, abdominal obesity, and wealthy nations in 2004. Endocrinology 2004;145:2633-2638.
8. McEwen BS. Central effects of stress hormones in health and disease: understanding the protective and damaging effects of stress and stress mediators. Eur J Pharmacol 2008;583:174-185.
9. Heim C, Nemeroff CB. The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies. Biol Psychiatry 2001;49:1023-1039.
10. Rinne T, De Kloet ER, Wouters L, Goekoop JG, Derijk RH, Van den Brink W. Hyperresponsiveness of hypothalamic-pituitary-adrenal axis to combined dexamethasone/corticotropin-releasing hormone challenge in female borderline personality disorder subjects with a history of sustained childhood abuse. Biol Psychiatry 2002;52:1102-1112.
11. Kunugi H, Hori H, Adachi N, Numakawa T. Interface between hypothalamic-pituitary-adrenal axis and brain-derived neurotrophic factor in depression. Psychiatry Clin Neurosci 2010;64:447-459.
12. Yehuda R. Status of glucocorticoid alterations in post-traumatic stress disorder. Ann N Y Acad Sci 2009;1179:56-69.
13. Heim C, Shugart M, Craighead WE, Nemeroff CB. Neurobiological and psychiatric consequences of child abuse and neglect. Dev Psychobiol 2010;52:671-690.
14. Carpenter LL, Tyrka AR, Ross NS, Khoury L, Anderson GM, Price LH. Effect of childhood emotional abuse and age on cortisol responsivity in adulthood. Biol Psychiatry 2009;66:69-75.
15. Tyrka AR, Wier L, Price LH et al. Childhood parental loss and adult hypothalamic-pituitary-adrenal function. Biol Psychiatry 2008;63:1147-1154.
16. Heim C, Newport DJ, Miller AH, Nemeroff CB. Long-term neuroendocrine effects of childhood maltreatment. JAMA 2000;284:2321.
17. McEwen BS. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev 2007;87:873-904.
18. Schulkin J. Angst and the amygdala. Dialogues Clin Neurosci 2006;8:407-416.
19. Duman CH, Schlesinger L, Terwilliger R, Russell DS, Newton SS, Duman RS. Peripheral insulin-like growth factor-I produces antidepressant-like behavior and contributes to the effect of exercise. Behav Brain Res 2009;198:366-371.
20. Schmidt HD, Duman RS. Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models. Neuropsychopharmacology 2010;35:2378-2391.
21. Dwivedi Y. Brain-derived neurotrophic factor and suicide pathogenesis. Ann Med 2010;42:87-96.
22. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008;64:527-532.
23. Elzinga BM, Molendijk ML, Oude Voshaar RC et al. The impact of childhood abuse and recent stress on serum brain-derived neurotrophic factor and the moderating role of BDNF Val66Met. Psychopharmacology 2011;214:319-328.
24. Jeon HJ, Kang ES, Lee EH et al. Childhood trauma and platelet brain-derived neurotrophic factor (BDNF) after a three month follow-up in patients with major depressive disorder. J Psychiatr Res 2012;46:966-972.
25. Mondelli V, Cattaneo A, Belvederi Murri M et al. Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume. J Clin Psychiatry 2011;72:1677-1684.
26. McCrory E, De Brito SA, Viding E. The impact of childhood maltreatment: a review of neurobiological and genetic factors. Front Psychiatry 2011;2:48.
27. Hart H, Rubia K. Neuroimaging of child abuse: a critical review. Front Hum Neurosci 2012;6:52.
28. Lanius RA, Bluhm RL, Frewen PA. How understanding the neurobiology of complex post-traumatic stress disorder can inform clinical practice: a social cognitive and affective neuroscience approach. Acta Psychiatr Scand 2011;124:331-348.
29. Philip NS, Sweet LH, Tyrka AR, Price LH, Bloom RF, Carpenter LL. Decreased default network connectivity is associated with early life stress in medication-free healthy adults. Eur Neuropsychopharmacol 2013;23:24-32.
30. Koenigs M, Grafman J. Posttraumatic stress disorder: the role of medial prefrontal cortex and amygdala. Neuroscientist 2009;15:540-548.
31. Carrion VG, Weems CF, Richert K, Hoffman BC, Reiss AL. Decreased prefrontal cortical volume associated with increased bedtime cortisol in traumatized youth. Biol Psychiatry 2010;68:491-493.
32. Carrion VG, Weems CF, Reiss AL. Stress predicts brain changes in children: a pilot longitudinal study on youth stress, posttraumatic stress disorder, and the hippocampus. Pediatrics 2007;119:509-516.
33. Treadway MT, Grant MM, Ding Z, Hollon SD, Gore JC, Shelton RC. Early adverse events, HPA activity and rostral anterior cingulate volume in MDD. PLoS ONE 2009;4:e4887.
34. Veer IM, Oei NY, Spinhoven P, van Buchem MA, Elzinga BM, Rombouts SA. Endogenous cortisol is associated with functional connectivity between the amygdala and medial prefrontal cortex. Psychoneuroendocrinology 2012;37:1039-1047.
35. Pechtel P, Pizzagalli DA. Effects of early life stress on cognitive and affective function: an integrated review of human literature. Psychopharmacology 2011;214:55-70.
36. De Bellis MD, Hooper SR, Spratt EG, Woolley DP. Neuropsychological findings in childhood neglect and their relationships to pediatric PTSD. J Int Neuropsychol Soc 2009;15:868-878.
37. Engert V, Efanov SI, Dedovic K, Duchesne A, Dagher A, Pruessner JC. Perceived early-life maternal care and the cortisol response to repeated psychosocial stress. J Psychiatry Neurosci 2010;35:370-377.
38. Dannlowski U, Stuhrmann A, Beutelmann V et al. Limbic scars: long-term consequences of childhood maltreatment revealed by functional and structural magnetic resonance imaging. Biol Psychiatry 2012;71:286-293.
39. Caspi A, Sugden K, Moffitt TE et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003;301:386-389.
40. Munafo MR, Durrant C, Lewis G, Flint J. Gene X environment interactions at the serotonin transporter locus. Biol Psychiatry 2009;65:211-219.
41. Risch N, Herrell R, Lehner T et al. Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. JAMA 2009;301:2462-2471.
42. Caspi A, Hariri AR, Holmes A, Uher R, Moffitt TE. Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am J Psychiatry 2010;167:509-527.
43. Karg K, Burmeister M, Shedden K, Sen S. The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation. Arch Gen Psychiatry 2011;68:444-454.
44. Nugent NR, Tyrka AR, Carpenter LL, Price LH. Gene-environment interactions: early life stress and risk for depressive and anxiety disorders. Psychopharmacology 2011;214:175-196.
45. Kranzler HR, Feinn R, Nelson EC et al. A CRHR1 haplotype moderates the effect of adverse childhood experiences on lifetime risk of major depressive episode in African-American women. Am J Med Genet B Neuropsychiatr Genet 2011;156B:960-968.
46. Grabe HJ, Schwahn C, Appel K et al. Childhood maltreatment, the corticotropin-releasing hormone receptor gene and adult depression in the general population. Am J Med Genet B Neuropsychiatr Genet 2010;153B:1483-1493.
47. Cicchetti D, Rogosch FA, Oshri A. Interactive effects of corticotropin releasing hormone receptor 1, serotonin transporter linked polymorphic region, and child maltreatment on diurnal cortisol regulation and internalizing symptomatology. Dev Psychopathol 2011;23:1125-1138.
48. Tyrka AR, Price LH, Gelernter J, Schepker C, Anderson GM, Carpenter LL. Interaction of childhood maltreatment with the corticotropin-releasing hormone receptor gene: effects on hypothalamic-pituitary-adrenal axis reactivity. Biol Psychiatry 2009;66:681-685.
49. Keers R, Uher R. Gene-environment interaction in major depression and antidepressant treatment response. Curr Psychiatry Rep 2012;14:129-137.
50. Keers R, Uher R, Huezo-Diaz P et al. Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project. Pharmacogenomics J 2011;11:138-145.
51. Murgatroyd C, Patchev AV, Wu Y et al. Dynamic DNA methylation programs persistent adverse effects of early-life stress. Nat Neurosci 2009;12:1559-1566.
52. Weaver IC, Cervoni N, Champagne FA et al. Epigenetic programming by maternal behavior. Nat Neurosci 2004;7:847-854.
53. McGowan PO, Sasaki A, D'Alessio AC et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci 2009;12:342-348.
54. Oberlander TF, Weinberg J, Papsdorf M, Grunau R, Misri S, Devlin AM. Prenatal exposure to maternal depression, neonatal methylation of human glucocorticoid receptor gene (NR3C1) and infant cortisol stress responses. Epigenetics 2008;3:97-106.
55. Radtke KM, Ruf M, Gunter HM et al. Transgenerational impact of intimate partner violence on methylation in the promoter of the glucocorticoid receptor. Transl Psychiatry 2011;1:e21.
56. Tyrka AR, Price LH, Marsit C, Walters OC, Carpenter LL. Childhood adversity and epigenetic modulation of the leukocyte glucocorticoid receptor: preliminary findings in healthy adults. PLoS ONE 2012;7:e30148.
57. Ursini G, Bollati V, Fazio L et al. Stress-related methylation of the catechol-O-methyltransferase Val 158 allele predicts human prefrontal cognition and activity. J Neurosci 2011;31:6692-6698.
58. Brown DW, Anda RF, Tiemeier H et al. Adverse childhood experiences and the risk of premature mortality. Am J Prev Med 2009;37:389-396.
59. Jones GT, Power C, Macfarlane GJ. Adverse events in childhood and chronic widespread pain in adult life: results from the 1958 British Birth Cohort Study. Pain 2009;143:92-96.
60. Epel ES. Psychological and metabolic stress: a recipe for accelerated cellular aging? Hormones (Athens) 2009;8:7-22.
61. Anagnostis P, Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Clinical review: the pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab 2009;94:2692-2701.
62. Tyrka AR, Walters OC, Price LH, Anderson GM, Carpenter LL. Altered response to neuroendocrine challenge linked to indices of the metabolic syndrome in healthy adults. Horm Metab Res 2012;44:543-549.
63. Miller GE, Chen E, Sze J et al. A functional genomic fingerprint of chronic stress in humans: blunted glucocorticoid and increased NF-kappaB signaling. Biol Psychiatry 2008;64:266-272.
64. Haroon E, Raison CL, Miller AH. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 2012;37:137-162.
65. Carpenter LL, Gawuga CE, Tyrka AR, Lee JK, Anderson GM, Price LH. Association between plasma IL-6 response to acute stress and early-life adversity in healthy adults. Neuropsychopharmacology 2010;35:2617-2623.
66. Danese A, Moffitt TE, Harrington H et al. Adverse childhood experiences and adult risk factors for age-related disease: depression, inflammation, and clustering of metabolic risk markers. Arch Pediatr Adolesc Med 2009;163:1135-1143.
67. Price LP, Kao HT, Burgers DE, Carpenter LL, Tyrka AR. Telomeres and early-life stress: an overview. Biol Psychiatry 2012;73:15-23.
68. Epel ES, Blackburn EH, Lin J et al. Accelerated telomere shortening in response to life stress. Proc Natl Acad Sci USA 2004;101:17312-17315.
69. Hardt J, Rutter M. Validity of adult retrospective reports of adverse childhood experiences: review of the evidence. J Child Psychol Psychiatry 2004;45:260-273.
70. Nanni V, Uher R, Danese A. Childhood maltreatment predicts unfavorable course of illness and treatment outcome in depression: a meta-analysis. Am J Psychiatry 2012;169:141-151.
71. Barbe RP, Bridge JA, Birmaher B, Kolko DJ, Brent DA. Lifetime history of sexual abuse, clinical presentation, and outcome in a clinical trial for adolescent depression. J Clin Psychiatry 2004;65:77-83.
72. Shamseddeen W, Asarnow JR, Clarke G et al. Impact of physical and sexual abuse on treatment response in the Treatment of Resistant Depression in Adolescent Study (TORDIA). J Am Acad Child Adolesc Psychiatry 2011;50:293-301.
73. Roberts NP, Kitchiner NJ, Kenardy J, Bisson JI. Early psychological interventions to treat acute traumatic stress symptoms. Cochrane Database Syst Rev 2010:CD007944.
74. Ellis B, Fogler J, Hansen S, Forbes P, Navalta C, Saxe G. Trauma systems therapy: 15-month outcomes and the importance of effecting environmental change. Psychol Trauma; Theory Research Pract Policy 2011;4:624-630.
75. Nemeroff CB, Heim CM, Thase ME et al. Differential responses to psychotherapy vs. pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci USA 2003;100:14293-14296.
76. Zobel I, Kech S, Van Calker D et al. Long-term effect of combined interpersonal psychotherapy and pharmacotherapy in a randomized trial of depressed patients. Acta Psychiatr Scand 2011;123:276-282.
77. Lynch TR, Trost WT, Salsman N, Linehan MM. Dialectical behavior therapy for borderline personality disorder. Annu Rev Clin Psychol 2007;3:181-205.
78. Steil R, Dyer A, Priebe K, Kleindienst N, Bohus M. Dialectical behavior therapy for posttraumatic stress disorder related to childhood sexual abuse: a pilot study of an intensive residential treatment program. J Trauma Stress 2011;24:102-106.
79. Foa EB. Prolonged exposure therapy: past, present, and future. Depress Anxiety 2011;28:1043-1047.
80. Cloitre M, Stovall-Mcclough KC, Nooner K et al. Treatment for PTSD related to childhood abuse: a randomized controlled trial. Am J Psychiatry 2010;167:915-924.
81. Nader K, Einarsson EO. Memory reconsolidation: an update. Ann N Y Acad Sci 2010;1191:27-41.
82. Karpova NN, Pickenhagen A, Lindholm J et al. Fear erasure in mice requires synergy between antidepressant drugs and extinction training. Science 2011;334:1731-1734.
83. Davis M. NMDA receptors and fear extinction: implications for cognitive behavioral therapy. Dialogues Clin Neurosci 2011;13:463-474.
84. Kleine RA, Hendriks GJ, Kusters WJ, Broekman TG, Van Minnen A. A randomized placebo-controlled trial of d-cycloserine to enhance exposure therapy for posttraumatic stress disorder. Biol Psychiatry 2012;71:962-968.
85. Litz BT, Salters-Pedneault K, Steenkamp MM et al. A randomized placebo-controlled trial of d-cycloserine and exposure therapy for posttraumatic stress disorder. J Psychiatr Res 2012;46:1184-1190.
86. Hoge EA, Worthington JJ, Nagurney JT et al. Effect of acute posttrauma propranolol on PTSD outcome and physiological responses during script-driven imagery. CNS Neurosci Ther 2012;18:21-27.
87. Brunet A, Poundja J, Tremblay J et al. Trauma reactivation under the influence of propranolol decreases posttraumatic stress symptoms and disorder: 3 open-label trials. J Clin Psychopharmacol 2011;31:547-550.
88. Zorrilla EP, Koob GF. Progress in corticotropin-releasing factor-1 antagonist development. Drug Discov Today 2010;15:371-383.
89. Griebel G, Beeske S, Stahl SM. The vasopressin V1b receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry 2012;73:1403-1411.
90. Griebel G, Holsboer F. Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning? Nat Rev Drug Discov 2012;11:462-478.
91. Wulsin AC, Herman JP, Solomon MB. Mifepristone decreases depression-like behavior and modulates neuroendocrine and central hypothalamic-pituitary-adrenocortical axis responsiveness to stress. Psychoneuroendocrinology 2010;35:1100-1112.
92. Pitman RK, Milad MR, Igoe SA et al. Systemic mifepristone blocks reconsolidation of cue-conditioned fear; propranolol prevents this effect. Behav Neurosci 2011;125:632-638.
93. Debattista C, Belanoff J. The use of mifepristone in the treatment of neuropsychiatric disorders. Trends Endocrinol Metab 2006;17:117-121.
94. Blasey CM, Block TS, Belanoff JK, Roe RL. Efficacy and safety of mifepristone for the treatment of psychotic depression. J Clin Psychopharmacol 2011;31:436-440.
95. Kling MA, Coleman VH, Schulkin J. Glucocorticoid inhibition in the treatment of depression: can we think outside the endocrine hypothalamus? Depress Anxiety 2009;26:641-649.
96. Zoladz JA, Pilc A. The effect of physical activity on the brain derived neurotrophic factor: from animal to human studies. J Physiol Pharmacol 2010;61:533-541.
97. Van Ijzendoorn MH, Caspers K, Bakermans-Kranenburg MJ, Beach SR, Philibert R. Methylation matters: interaction between methylation density and serotonin transporter genotype predicts unresolved loss or trauma. Biol Psychiatry 2010;68:405-407.
98. Eley TC, Hudson JL, Creswell C et al. Therapygenetics: the 5HTTLPR and response to psychological therapy. Mol Psychiatry 2012;17:236-237.
99. Bohacek J, Mansuy IM. Epigenetic inheritance of disease and disease risk. Neuropsychopharmacology 2012;38:220-236.
100. McGowan PO, Szyf M. The epigenetics of social adversity in early life: implications for mental health outcomes. Neurobiol Dis 2010;39:66-72.
101. Gomez-Pinilla F, Zhuang Y, Feng J, Ying Z, Fan G. Exercise impacts brain-derived neurotrophic factor plasticity by engaging mechanisms of epigenetic regulation. Eur J Neurosci 2011;33:383-390.
102. Miyaoka T, Wake R, Furuya M et al. Minocycline as adjunctive therapy for patients with unipolar psychotic depression: an open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2012;37:222-226.
103. Lotrich FE, Sears B, McNamara RK. Elevated ratio of arachidonic acid to long-chain omega-3 fatty acids predicts depression development following interferon-alpha treatment: relati onship with interleukin-6. Brain Behav Immun 2013;31:48-53.
104. Raison CL, Rutherford RE, Woolwine BJ et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2012;70:31-41.
105. Sepanjnia K, Modabbernia A, Ashrafi M, Modabbernia MJ, Akhondzadeh S. Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial. Neuropsychopharmacology 2012;37:2093-2100.
106. Martins JG, Bentsen H, Puri BK. Eicosapentaenoic acid appears to be the key omega-3 fatty acid component associated with efficacy in major depressive disorder: a critique of Bloch and Hannestad and updated meta-analysis. Mol Psychiatry 2012;17:1144-1149.
107. Lewitus GM, Schwartz M. Behavioral immunization: immunity to self-antigens contributes to psychological stress resilience. Mol Psychiatry 2009;14:532-536.